PMID: 9537199Apr 16, 1998Paper

Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C

American Journal of Clinical Oncology
L LetendreAyalew Tefferi

Abstract

We have evaluated the activity and toxicity of cytosine arabinoside (ara-C; 750 mg/m2 intravenously given over 3 hours every 12 hours for 12 doses) to induce remission in older (median age, 73 years) newly diagnosed patients who had acute myelogenous leukemia (AML). A maximum of two cycles of induction were administered. Patients who achieved complete remission could receive three additional consolidation courses limited to 4 to 6 doses of ara-C every 12 hours, depending on marrow cellularity. Thirty patients were evaluable. Twenty-two patients had one or more unfavorable prognostic factors, including antecedent hematologic disorders (10), cytogenetic abnormalities (17), or hyperleucocytosis (5). Fourteen patients (47%) achieved complete remission. Four patients did not receive consolidation as planned because of medical contraindication or refusal, and three patients relapsed during consolidation. The median duration of complete remission was 326 days. Sixteen patients failed induction because of relative or absolute drug resistance in nine patients, or death in seven patients. Median survival for the entire group was 6 months. Toxicity was significant, with a median initial hospitalization of 29 days. These results are compar...Continue Reading

References

Nov 1, 1976·Archives of Internal Medicine·R E EnckJ M Bennett
Apr 1, 1991·European Journal of Haematology·A WahlinH Jonsson
Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
Aug 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B KahnJ H Glick
Apr 1, 1995·Leukemia Research·J M Bennett
Jan 1, 1994·British Journal of Haematology·M BaudardR Zittoun

❮ Previous
Next ❯

Citations

Sep 5, 2002·Drugs & Aging·Graham H Jackson, Penelope R A Taylor
Mar 28, 2012·Disease-a-month : DM·Robert Frank Cornell, Jeanne Palmer
Aug 29, 2013·Protein & Cell·Grace L PeloquinAmir T Fathi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.